Hims & Hers Health, INC Form 4 insider transactions

Director Christiane Pendarvis of Hims & Hers Health, Inc. reports the vesting of 15,210 Restricted Stock Units (RSUs) on March 15, 2024, convertible to Class A Common Stock.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, reports the vesting and disposal of restricted stock units (RSUs) to cover tax obligations.

Oluyemi Okupe, CFO of Hims & Hers Health, reports the vesting and disposal of restricted stock units to cover tax obligations.

Director David B. Wells reports the acquisition of 10,044 shares of Class A Common Stock and the disposition of 10,044 Restricted Stock Units of Hims & Hers Health, Inc.

Director Ambar Bhattacharyya reports the vesting of restricted stock units (RSUs) into Class A Common Stock of Hims & Hers Health, Inc.

Director Alex Bard reports acquisition and disposal of Hims & Hers Health, Inc. Class A Common Stock and Restricted Stock Units.

Chief Medical Officer Patrick Harrison Carroll of Hims & Hers Health, Inc. reports the vesting and disposal of restricted stock units to cover tax obligations.

Andrew Dudum, CEO of Hims & Hers Health, reports the vesting and settlement of restricted stock units and related tax withholding.

Michael Chi, Chief Marketing Officer of Hims & Hers Health, Inc., reported the vesting and subsequent sale of shares to cover tax obligations related to restricted stock units.

Director Andrea Perez Garcia reports vesting of restricted stock units in Hims & Hers Health, Inc.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc., reports the vesting and disposal of restricted stock units (RSUs) to cover tax obligations.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., executed stock option exercises and sales of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Chief Operating Officer of Hims & Hers Health, Melissa Baird, reports exercising stock options and selling Class A Common Stock between March 5th and March 7th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Irene Becklund, PAO of Hims & Hers Health, sold 2,747 shares of Class A Common Stock and was granted 69,518 Restricted Stock Units (RSUs).

Oluyemi Okupe, CFO of Hims & Hers Health, exercised stock options and sold shares of Class A Common Stock on March 4, 2024, according to a Form 4 filing with the SEC.

Irene Becklund, PAO of Hims & Hers Health, executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on March 1, 2024, according to a Form 4 filing with the SEC.

Director and Chief Medical Officer Patrick Harrison Carroll sold 20,000 shares of Hims & Hers Health, Inc. and acquired 77,433 restricted stock units.

Oluyemi Okupe, CFO of Hims & Hers Health, reports the acquisition of 367,809 Restricted Stock Units (RSUs) tied to Class A Common Stock.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc., reports the acquisition of 418,141 Restricted Stock Units (RSUs) on February 28, 2024, according to a Form 4 filing with the SEC.

Michael Chi, Chief Marketing Officer of Hims & Hers Health, Inc., reports the sale of 47,687 shares of Class A Common Stock at $13.19 per share and the grant of 309,734 Restricted Stock Units (RSUs).

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., acquired 193,584 Restricted Stock Units (RSUs) on February 28, 2024, according to a Form 4 filing with the SEC.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on February 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director David B. Wells sold 260,000 shares of Hims & Hers Health, Inc. at an average price of $13.1585 on February 28, 2024.

Irene Becklund, PAO of Hims & Hers Health, sold 2,747 shares of Class A Common Stock at $12.08 per share on February 27, 2024, under a pre-arranged 10b5-1 trading plan.